Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of JW0104 and C2207 in Healthy Adults
NCT06378684Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JW0104 in dyslipidemia and hypertension (HTN) (6 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Maximum Plasma Concentration at Steady State and Area Under the Curve over the Dosing Interval at Steady State. Started Sep 2023; status: completed.
02
Drugs
JW0104
03
Conditions
dyslipidemiahypertension (HTN)
Beyond the preview
Go deeper on NCT06378684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378684.